Selected research
Industry Research
Neuroendocrine Tumor Drug Industry Research Report 2026
Market perspective
The global Neuroendocrine Tumor Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Neuroendocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Neuroendocrine Tumor Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Neuroendocrine Tumor Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Neuroendocrine Tumor Drug include Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, Intezyne, Inc, INVENT Pharmaceuticals, Inc., Ipsen S.A., Karyopharm Therapeutics, Inc., Lexicon Pharmaceuticals, Inc. and Midatech Pharma Plc ., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Neuroendocrine Tumor Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neuroendocrine Tumor Drug Market by Company
Exelixis, Inc.
Foresee Pharmaceuticals, LLC
Hutchison MediPharma Limited
Intezyne, Inc
INVENT Pharmaceuticals, Inc.
Ipsen S.A.
Karyopharm Therapeutics, Inc.
Lexicon Pharmaceuticals, Inc.
Midatech Pharma Plc .
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Northwest Biotherapeutics, Inc.
OctreoPharm Sciences GmbH
OXiGENE, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Novartis AG
Eisai
Neuroendocrine Tumor Drug Segment by Type
mTOR Protein Inhibitors
Tyrosine Kinase 3 Inhibitors
Growth Hormone Releasing Factor Antagonists
Somatostatin Receptor Agonists
Somatostatin Receptor Antagonists
Others
Neuroendocrine Tumor Drug Segment by Application
Hospital
Clinic
Others
Neuroendocrine Tumor Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neuroendocrine Tumor Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neuroendocrine Tumor Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neuroendocrine Tumor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- mTOR Protein Inhibitors
- Tyrosine Kinase 3 Inhibitors
- Growth Hormone Releasing Factor Antagonists
- Somatostatin Receptor Agonists
- Somatostatin Receptor Antagonists
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Exelixis, Inc.
- Foresee Pharmaceuticals, LLC
- Hutchison MediPharma Limited
- Intezyne, Inc
- INVENT Pharmaceuticals, Inc.
- Ipsen S.A.
- Karyopharm Therapeutics, Inc.
- Lexicon Pharmaceuticals, Inc.
- Midatech Pharma Plc .
- Millennium Pharmaceuticals, Inc.
- MolMed S.p.A.
- Northwest Biotherapeutics, Inc.
- OctreoPharm Sciences GmbH
- OXiGENE, Inc.
- Jiangsu Hengrui Medicine Co., Ltd.
- Novartis AG
- Eisai
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Neuroendocrine Tumor Drug Market Size (2021-2032)
- 2.2.2 Global Neuroendocrine Tumor Drug Sales (2021-2032)
- 2.2.3 Global Neuroendocrine Tumor Drug Market Average Price (2021-2032)
- 2.3 Neuroendocrine Tumor Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 mTOR Protein Inhibitors
- 2.3.3 Tyrosine Kinase 3 Inhibitors
- 2.3.4 Growth Hormone Releasing Factor Antagonists
- 2.3.5 Somatostatin Receptor Agonists
- 2.3.6 Somatostatin Receptor Antagonists
- 2.3.7 Others
- 2.4 Neuroendocrine Tumor Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Neuroendocrine Tumor Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Neuroendocrine Tumor Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Neuroendocrine Tumor Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Neuroendocrine Tumor Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Neuroendocrine Tumor Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Neuroendocrine Tumor Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Neuroendocrine Tumor Drug, Product Type & Application
- 3.8 Global Manufacturers of Neuroendocrine Tumor Drug, Established Date
- 3.9 Global Neuroendocrine Tumor Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Exelixis, Inc.
- 4.1.1 Exelixis, Inc. Company Information
- 4.1.2 Exelixis, Inc. Business Overview
- 4.1.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.1.5 Exelixis, Inc. Recent Developments
- 4.2 Foresee Pharmaceuticals, LLC
- 4.2.1 Foresee Pharmaceuticals, LLC Company Information
- 4.2.2 Foresee Pharmaceuticals, LLC Business Overview
- 4.2.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio
- 4.2.5 Foresee Pharmaceuticals, LLC Recent Developments
- 4.3 Hutchison MediPharma Limited
- 4.3.1 Hutchison MediPharma Limited Company Information
- 4.3.2 Hutchison MediPharma Limited Business Overview
- 4.3.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio
- 4.3.5 Hutchison MediPharma Limited Recent Developments
- 4.4 Intezyne, Inc
- 4.4.1 Intezyne, Inc Company Information
- 4.4.2 Intezyne, Inc Business Overview
- 4.4.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio
- 4.4.5 Intezyne, Inc Recent Developments
- 4.5 INVENT Pharmaceuticals, Inc.
- 4.5.1 INVENT Pharmaceuticals, Inc. Company Information
- 4.5.2 INVENT Pharmaceuticals, Inc. Business Overview
- 4.5.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.5.5 INVENT Pharmaceuticals, Inc. Recent Developments
- 4.6 Ipsen S.A.
- 4.6.1 Ipsen S.A. Company Information
- 4.6.2 Ipsen S.A. Business Overview
- 4.6.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio
- 4.6.5 Ipsen S.A. Recent Developments
- 4.7 Karyopharm Therapeutics, Inc.
- 4.7.1 Karyopharm Therapeutics, Inc. Company Information
- 4.7.2 Karyopharm Therapeutics, Inc. Business Overview
- 4.7.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.7.5 Karyopharm Therapeutics, Inc. Recent Developments
- 4.8 Lexicon Pharmaceuticals, Inc.
- 4.8.1 Lexicon Pharmaceuticals, Inc. Company Information
- 4.8.2 Lexicon Pharmaceuticals, Inc. Business Overview
- 4.8.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.8.5 Lexicon Pharmaceuticals, Inc. Recent Developments
- 4.9 Midatech Pharma Plc .
- 4.9.1 Midatech Pharma Plc . Company Information
- 4.9.2 Midatech Pharma Plc . Business Overview
- 4.9.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio
- 4.9.5 Midatech Pharma Plc . Recent Developments
- 4.10 Millennium Pharmaceuticals, Inc.
- 4.10.1 Millennium Pharmaceuticals, Inc. Company Information
- 4.10.2 Millennium Pharmaceuticals, Inc. Business Overview
- 4.10.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.10.5 Millennium Pharmaceuticals, Inc. Recent Developments
- 4.11 MolMed S.p.A.
- 4.11.1 MolMed S.p.A. Company Information
- 4.11.2 MolMed S.p.A. Business Overview
- 4.11.3 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio
- 4.11.5 MolMed S.p.A. Recent Developments
- 4.12 Northwest Biotherapeutics, Inc.
- 4.12.1 Northwest Biotherapeutics, Inc. Company Information
- 4.12.2 Northwest Biotherapeutics, Inc. Business Overview
- 4.12.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.12.5 Northwest Biotherapeutics, Inc. Recent Developments
- 4.13 OctreoPharm Sciences GmbH
- 4.13.1 OctreoPharm Sciences GmbH Company Information
- 4.13.2 OctreoPharm Sciences GmbH Business Overview
- 4.13.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio
- 4.13.5 OctreoPharm Sciences GmbH Recent Developments
- 4.14 OXiGENE, Inc.
- 4.14.1 OXiGENE, Inc. Company Information
- 4.14.2 OXiGENE, Inc. Business Overview
- 4.14.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio
- 4.14.5 OXiGENE, Inc. Recent Developments
- 4.15 Jiangsu Hengrui Medicine Co., Ltd.
- 4.15.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
- 4.15.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
- 4.15.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio
- 4.15.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
- 4.16 Novartis AG
- 4.16.1 Novartis AG Company Information
- 4.16.2 Novartis AG Business Overview
- 4.16.3 Novartis AG Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Novartis AG Neuroendocrine Tumor Drug Product Portfolio
- 4.16.5 Novartis AG Recent Developments
- 4.17 Eisai
- 4.17.1 Eisai Company Information
- 4.17.2 Eisai Business Overview
- 4.17.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Eisai Neuroendocrine Tumor Drug Product Portfolio
- 4.17.5 Eisai Recent Developments
5 Global Neuroendocrine Tumor Drug Market Scenario by Region
- 5.1 Global Neuroendocrine Tumor Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Neuroendocrine Tumor Drug Sales by Region: 2021-2032
- 5.2.1 Global Neuroendocrine Tumor Drug Sales by Region: 2021-2026
- 5.2.2 Global Neuroendocrine Tumor Drug Sales by Region: 2027-2032
- 5.3 Global Neuroendocrine Tumor Drug Revenue by Region: 2021-2032
- 5.3.1 Global Neuroendocrine Tumor Drug Revenue by Region: 2021-2026
- 5.3.2 Global Neuroendocrine Tumor Drug Revenue by Region: 2027-2032
- 5.4 North America Neuroendocrine Tumor Drug Market Facts & Figures by Country
- 5.4.1 North America Neuroendocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Neuroendocrine Tumor Drug Sales by Country (2021-2032)
- 5.4.3 North America Neuroendocrine Tumor Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Neuroendocrine Tumor Drug Market Facts & Figures by Country
- 5.5.1 Europe Neuroendocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Neuroendocrine Tumor Drug Sales by Country (2021-2032)
- 5.5.3 Europe Neuroendocrine Tumor Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Neuroendocrine Tumor Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Neuroendocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Neuroendocrine Tumor Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Neuroendocrine Tumor Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Neuroendocrine Tumor Drug Market Facts & Figures by Country
- 5.7.1 South America Neuroendocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Neuroendocrine Tumor Drug Sales by Country (2021-2032)
- 5.7.3 South America Neuroendocrine Tumor Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Neuroendocrine Tumor Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Neuroendocrine Tumor Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Neuroendocrine Tumor Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Neuroendocrine Tumor Drug Sales by Type (2021-2032)
- 6.1.1 Global Neuroendocrine Tumor Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Neuroendocrine Tumor Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Neuroendocrine Tumor Drug Revenue by Type (2021-2032)
- 6.2.1 Global Neuroendocrine Tumor Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Neuroendocrine Tumor Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Neuroendocrine Tumor Drug Sales by Application (2021-2032)
- 7.1.1 Global Neuroendocrine Tumor Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Neuroendocrine Tumor Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Neuroendocrine Tumor Drug Revenue by Application (2021-2032)
- 7.2.1 Global Neuroendocrine Tumor Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Neuroendocrine Tumor Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Neuroendocrine Tumor Drug Value Chain Analysis
- 8.1.1 Neuroendocrine Tumor Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Neuroendocrine Tumor Drug Production Mode & Process
- 8.2 Neuroendocrine Tumor Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Neuroendocrine Tumor Drug Distributors
- 8.2.3 Neuroendocrine Tumor Drug Customers
9 Global Neuroendocrine Tumor Drug Analyzing Market Dynamics
- 9.1 Neuroendocrine Tumor Drug Industry Trends
- 9.2 Neuroendocrine Tumor Drug Industry Drivers
- 9.3 Neuroendocrine Tumor Drug Industry Opportunities and Challenges
- 9.4 Neuroendocrine Tumor Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst